<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289820</url>
  </required_header>
  <id_info>
    <org_study_id>D4420C00004</org_study_id>
    <nct_id>NCT02289820</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults</brief_title>
  <official_title>A Phase 1b Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the safety, tolerability and immunogenicity of
      ascending doses of adjuvant in combination with a single dosage level of RSV sF in adults 60
      years or older who are healthy or who have stable, chronic underlying medical conditions.
      This study will also provide preliminary safety and immunogenicity data to support concurrent
      dosing of MEDI7510 with influenza vaccine (IIV), and to assess the safety of MEDI7510 at a
      dose previously assessed in the Phase 1a study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1b, double-blind, randomized, controlled cohort escalation study evaluating the
      safety, tolerability and immunogenicity of MEDI7510.

      Approximately 264 subjects will be enrolled at approximately 5 study centers in the US and
      randomized by cohort (Cohort 1 [4:1]; Cohorts 2 and 3 [8:8:3]; Cohort 4 [5:1]) to receive a
      single intramuscular dose of 1 study vaccine (Cohorts 1 and 4) or a single intramuscular dose
      of each of 2 study vaccines (Cohorts 2 and 3) administered in contralateral arms.

      Cohort 1: MEDI7510 formulation (n = 40) or IIV (n = 10) Cohort 2: MEDI7510 formulation and
      placebo (n = 40) or MEDI7510 formulation and IIV (n = 40) or placebo and IIV (n = 15) Cohort
      3: MEDI7510 formulation and placebo (n = 40) or MEDI7510 formulation and IIV (n = 40) or
      placebo and IIV (n = 15) Cohort 4: MEDI7510 formulation (n = 20) or IIV (n = 4)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2015</start_date>
  <completion_date type="Actual">February 24, 2016</completion_date>
  <primary_completion_date type="Actual">February 24, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Symptoms</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Solicited symptoms are events that are considered likely to occur post dosing and included the local reaction (pain, tenderness or soreness, redness, and swelling at the site of injection) to investigational product (IP) injection and systemic symptoms (fever greater than or equal to [&gt;=] 100.4°F [&gt;=38°C] by any route, headache, generalized muscle aches, and fatigue or tiredness) that might be related to IP injection. Solicited symptoms were not coded using Medical Dictionary for Regulatory Activities (MedDRA) and summarized regardless of whether or not they are treatment emergent. The percentage of participants with solicited symptoms were recorded during Days 1 (day of dosing) through 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From Day 1 to Day 29</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Treatment-emergent were the events between administration of study drug and including the follow-up period through Day 29. The AEs were summarized using the Medical Dictionary for Regulatory Activities version 18.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-emergent Serious Adverse Events</measure>
    <time_frame>From Day 1 to Day 361</time_frame>
    <description>A serious adverse event (SAE) was an AE resulting in any of following reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk), persistent or significant disability/incapacity, congenital anomaly, and a medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With New Onset Chronic Diseases (NOCDs)</measure>
    <time_frame>From Day 1 to Day 361</time_frame>
    <description>A NOCD was a newly diagnosed medical condition that is of a chronic, ongoing nature. It was observed after receiving study drug and was assessed by investigator as medically significant. All NOCDs were recorded from the time of dosing through the day of the last participant contact (Day 361 visit).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)</measure>
    <time_frame>From Day 1 to Day 361</time_frame>
    <description>An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. Treatment emergent AESIs were collected from the time of dosing through the day of the last participant contact (Day 361 visit).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</measure>
    <time_frame>Baseline (Day 1), Day 29, 61, 91, 181, 271, and 361</time_frame>
    <description>GMTs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay at Baseline and the results through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A. Immunogenicity population is defined as all participants in ATP who had no protocol deviation judged to have the potential to interfere with generation or interpretation of an immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rises (GMFRs) of Serum Antibodies Against RSV by RSV A Microneutralization Assay</measure>
    <time_frame>Day 29, 61, 91, 181, 271, and 361</time_frame>
    <description>GMFRs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay from Baseline line through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Post-dose Seroresponse to RSV by RSV A Microneutralization Assay</measure>
    <time_frame>Day 29</time_frame>
    <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise in titer from baseline. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations of Serum Antibodies Against RSV by Anti F Immunoglobulin G (IgG) Assay</measure>
    <time_frame>Baseline (Day 1), Day 29, 61, 91, 181, 271, and 361</time_frame>
    <description>Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFRs of Serum Antibodies Against RSV by Anti F IgG Assay</measure>
    <time_frame>Day 29, 61, 91, 181, 271, and 361</time_frame>
    <description>The Anti F IgG antibodies were derived from the RSV-specific 4-plex MSD assay developed on the Meso Scale discovery platform. Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Post-dose Seroresponse to RSV by Anti-F IgG Assay</measure>
    <time_frame>Day 29</time_frame>
    <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise from baseline. Humoral immunity against RSV was assessed by an Anti-F IgG assay derived from the RSV-specific 4-plex MSD assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratios of GMTs and GMFRs of Hemagglutination Inhibition (HAI) Antibodies</measure>
    <time_frame>Day 29</time_frame>
    <description>The ratio of post-dose HAI antibody GMTs and GMFRs in the IIV group and the MEDI7510 plus IIV group was provided by strain and by cohort for Cohorts 2 and 3 to check the effect of MEDI7510 on IIV when administered together. Humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed on Day 29 by each strain (H1N1, H3N2, B/Yamagata).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Counts of Cellular Immune Response Against RSV by Respiratory Syncytial Virus Fusion Protein (RSV F) Interferon Gamma (IFNγ) Enzyme-linked Immunosorbent Spot (ELISPOT) Assay</measure>
    <time_frame>Baseline (Day 1) and Day 8</time_frame>
    <description>The Geometric Mean Counts assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFRs of Cellular Immune Response Against RSV by RSV F IFNγ ELISPOT Assay</measure>
    <time_frame>Day 8</time_frame>
    <description>The GMFRs assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Post-dose Cell-mediated Immune Response to RSV F by RSV F Peptide Pool IFNγ ELISPOT</measure>
    <time_frame>Day 8</time_frame>
    <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise from baseline. The Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Respiratory Syncytial Virus (RSV)</condition>
  <arm_group>
    <arm_group_label>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactivated Influenza Vaccine (IIV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI7510</intervention_name>
    <description>RSV sF antigen plus adjuvant</description>
    <arm_group_label>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</arm_group_label>
    <arm_group_label>MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2</arm_group_label>
    <arm_group_label>MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3</arm_group_label>
    <arm_group_label>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IIV</intervention_name>
    <description>Marketed Inactivated Influenza Vaccine</description>
    <arm_group_label>MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2</arm_group_label>
    <arm_group_label>Inactivated Influenza Vaccine (IIV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 60 years

          -  Ambulatory or ambulatory with assistance (not institutionalized, bedridden, or
             homebound)

          -  Weight greater than 90 lbs

          -  Hemoglobin greater than or equal to 10.5 g/dL for women and greater than or equal to
             11 g/dL for men

          -  Subject able to complete follow-up period of 360 days after dosing

        Exclusion Criteria:

          -  History of allergy to: any component of the vaccine; IIV or intolerance of IIV; eggs
             in adulthood

          -  Receipt of seasonal flu shot within 60 days prior to dosing

          -  Any unstable acute or chronic medical condition, including one that has resulted in
             change in therapy (medication or other) in the 30 days prior to randomization or
             hospitalization in the previous year or might be predicted to result in
             hospitalization in the year after enrollment. Subjects with severe, untreated or
             uncontrolled underlying medical disease that might either compromise subject safety or
             affect the ability to assess safety of the investigational product are excluded.
             Medications taken on an as-needed basis are permitted to start or stop during the 30
             days prior to randomization unless they are medications not previously taken by the
             subject

          -  Clinically significant abnormalities in screening laboratory assessments or screening
             ECG

          -  History of hepatitis B or hepatitis C infection

          -  History of Guillain-Barré syndrome

          -  Cognitive disorder such that informed consent cannot be obtained directly from the
             subject

          -  Previous vaccination against RSV

          -  History of or current autoimmune disorder

          -  Immunosuppression caused by disease, including human immunodeficiency virus (HIV)
             infection, or medications. Any oral prednisone dosing within 30 days of enrollment or
             planned dosing within the 360-day follow-up period would disqualify. Expected need for
             immunosuppressive medications during the 360-day follow-up period would disqualify

          -  History of splenectomy or of condition affecting splenic function (eg,
             hemoglobinopathy)

          -  History of cancer within preceding 5 years other than treated non-melanoma skin cancer

          -  Body Mass Index 40 or higher

          -  Receipt of any nonstudy vaccine within 30 days prior to study dosing or expected
             receipt of nonstudy vaccine within 30 days after study dosing

          -  Receipt of any investigational product in the 90 days prior to randomization or
             expected receipt of investigational product during the period of study follow-up

          -  Receipt of immunoglobulins or blood products within 4 months of study dosing (120
             days) or expected receipt of investigational product during the period of study
             follow-up

          -  Current bleeding or clotting disorder including use of anticoagulants other than drugs
             with anti-platelet activity (such as nonsteroidal anti-inflammatory drugs,
             clopidogrel, ticagrelor or aspirin)

          -  Expected receipt of antipyretic or analgesic medication on a daily or every other day
             basis from randomization through 72 hours after receipt of IP (Note: A daily dose of
             aspirin is not considered a contraindication to enrollment.)

          -  Subjects who have significant scarring, tattoos, abrasions, cuts, or infections over
             the deltoid region of both arms that, in the investigators opinion, could interfere
             with evaluation of injection site local reactions

          -  Concurrent enrollment in another clinical study that involves any invasive clinical
             procedure, including phlebotomy

          -  History of alcohol or drug abuse or psychiatric disorder that, in the investigators
             opinion, would affect the subject's safety or compliance with study

          -  Employees of individuals directly involved with the conduct of the study, individuals
             who themselves are involved with the conduct of the study, or immediate family members
             of such individuals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith Falloon, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Sheldon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Curtis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Compass Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Ervin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Center for Pharmaceutical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wayne Harper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. Keipp Talbot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <results_first_submitted>January 30, 2017</results_first_submitted>
  <results_first_submitted_qc>August 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 16, 2018</results_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RSV</keyword>
  <keyword>Older adults</keyword>
  <keyword>MEDI7510</keyword>
  <keyword>Vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 363 participants were screened. Of these, 264 participants were enrolled.</recruitment_details>
      <pre_assignment_details>A total of 264 participants were enrolled in the study. Of the 264 randomized participants, 3 participants did not receive the study drug. 261 participants were included in the As-treated Population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
          <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
          <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Inactivated Influenza Vaccine (IIV)</title>
          <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>MEDI7510 (120 mcg sF + 5 mcg GLA)+ IIV, Cohort 3</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="40"/>
                <participants group_id="P7" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
          <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Inactivated Influenza Vaccine (IIV)</title>
          <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>MEDI7510 (120 mcg sF + 5 mcg GLA)+ IIV, Cohort 3</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
          <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="40"/>
            <count group_id="B6" value="39"/>
            <count group_id="B7" value="20"/>
            <count group_id="B8" value="261"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="6.9"/>
                    <measurement group_id="B2" value="69.6" spread="7.0"/>
                    <measurement group_id="B3" value="69.3" spread="5.2"/>
                    <measurement group_id="B4" value="67.9" spread="5.8"/>
                    <measurement group_id="B5" value="70.1" spread="5.9"/>
                    <measurement group_id="B6" value="70.2" spread="6.8"/>
                    <measurement group_id="B7" value="68.9" spread="6.5"/>
                    <measurement group_id="B8" value="69.5" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Symptoms</title>
        <description>Solicited symptoms are events that are considered likely to occur post dosing and included the local reaction (pain, tenderness or soreness, redness, and swelling at the site of injection) to investigational product (IP) injection and systemic symptoms (fever greater than or equal to [&gt;=] 100.4°F [&gt;=38°C] by any route, headache, generalized muscle aches, and fatigue or tiredness) that might be related to IP injection. Solicited symptoms were not coded using Medical Dictionary for Regulatory Activities (MedDRA) and summarized regardless of whether or not they are treatment emergent. The percentage of participants with solicited symptoms were recorded during Days 1 (day of dosing) through 7.</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>As-treated Population (ATP) included all participants who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Symptoms</title>
          <description>Solicited symptoms are events that are considered likely to occur post dosing and included the local reaction (pain, tenderness or soreness, redness, and swelling at the site of injection) to investigational product (IP) injection and systemic symptoms (fever greater than or equal to [&gt;=] 100.4°F [&gt;=38°C] by any route, headache, generalized muscle aches, and fatigue or tiredness) that might be related to IP injection. Solicited symptoms were not coded using Medical Dictionary for Regulatory Activities (MedDRA) and summarized regardless of whether or not they are treatment emergent. The percentage of participants with solicited symptoms were recorded during Days 1 (day of dosing) through 7.</description>
          <population>As-treated Population (ATP) included all participants who received any amount of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9"/>
                    <measurement group_id="O2" value="73.7"/>
                    <measurement group_id="O3" value="60.0"/>
                    <measurement group_id="O4" value="60.0"/>
                    <measurement group_id="O5" value="63.6"/>
                    <measurement group_id="O6" value="75.0"/>
                    <measurement group_id="O7" value="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Treatment-emergent were the events between administration of study drug and including the follow-up period through Day 29. The AEs were summarized using the Medical Dictionary for Regulatory Activities version 18.1.</description>
        <time_frame>From Day 1 to Day 29</time_frame>
        <population>ATP included all participants who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Treatment-emergent were the events between administration of study drug and including the follow-up period through Day 29. The AEs were summarized using the Medical Dictionary for Regulatory Activities version 18.1.</description>
          <population>ATP included all participants who received any amount of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1"/>
                    <measurement group_id="O2" value="15.4"/>
                    <measurement group_id="O3" value="22.5"/>
                    <measurement group_id="O4" value="30.0"/>
                    <measurement group_id="O5" value="18.2"/>
                    <measurement group_id="O6" value="27.5"/>
                    <measurement group_id="O7" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-emergent Serious Adverse Events</title>
        <description>A serious adverse event (SAE) was an AE resulting in any of following reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk), persistent or significant disability/incapacity, congenital anomaly, and a medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above.</description>
        <time_frame>From Day 1 to Day 361</time_frame>
        <population>ATP included all participants who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-emergent Serious Adverse Events</title>
          <description>A serious adverse event (SAE) was an AE resulting in any of following reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk), persistent or significant disability/incapacity, congenital anomaly, and a medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above.</description>
          <population>ATP included all participants who received any amount of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2.3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With New Onset Chronic Diseases (NOCDs)</title>
        <description>A NOCD was a newly diagnosed medical condition that is of a chronic, ongoing nature. It was observed after receiving study drug and was assessed by investigator as medically significant. All NOCDs were recorded from the time of dosing through the day of the last participant contact (Day 361 visit).</description>
        <time_frame>From Day 1 to Day 361</time_frame>
        <population>ATP included all participants who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Onset Chronic Diseases (NOCDs)</title>
          <description>A NOCD was a newly diagnosed medical condition that is of a chronic, ongoing nature. It was observed after receiving study drug and was assessed by investigator as medically significant. All NOCDs were recorded from the time of dosing through the day of the last participant contact (Day 361 visit).</description>
          <population>ATP included all participants who received any amount of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="5.0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)</title>
        <description>An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. Treatment emergent AESIs were collected from the time of dosing through the day of the last participant contact (Day 361 visit).</description>
        <time_frame>From Day 1 to Day 361</time_frame>
        <population>ATP included all participants who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)</title>
          <description>An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. Treatment emergent AESIs were collected from the time of dosing through the day of the last participant contact (Day 361 visit).</description>
          <population>ATP included all participants who received any amount of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2.5"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</title>
        <description>GMTs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay at Baseline and the results through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A. Immunogenicity population is defined as all participants in ATP who had no protocol deviation judged to have the potential to interfere with generation or interpretation of an immune response.</description>
        <time_frame>Baseline (Day 1), Day 29, 61, 91, 181, 271, and 361</time_frame>
        <population>Immunogenicity population</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</title>
          <description>GMTs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay at Baseline and the results through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A. Immunogenicity population is defined as all participants in ATP who had no protocol deviation judged to have the potential to interfere with generation or interpretation of an immune response.</description>
          <population>Immunogenicity population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441.15" lower_limit="344.99" upper_limit="564.11"/>
                    <measurement group_id="O2" value="397.52" lower_limit="279.60" upper_limit="565.17"/>
                    <measurement group_id="O3" value="401.85" lower_limit="313.66" upper_limit="514.82"/>
                    <measurement group_id="O4" value="504.78" lower_limit="332.66" upper_limit="765.95"/>
                    <measurement group_id="O5" value="513.53" lower_limit="414.42" upper_limit="636.36"/>
                    <measurement group_id="O6" value="365.19" lower_limit="275.62" upper_limit="483.87"/>
                    <measurement group_id="O7" value="510.88" lower_limit="416.00" upper_limit="627.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1068.43" lower_limit="820.93" upper_limit="1390.57"/>
                    <measurement group_id="O2" value="1233.62" lower_limit="1010.37" upper_limit="1506.21"/>
                    <measurement group_id="O3" value="1004.49" lower_limit="839.19" upper_limit="1202.36"/>
                    <measurement group_id="O4" value="1217.75" lower_limit="867.21" upper_limit="1709.98"/>
                    <measurement group_id="O5" value="464.13" lower_limit="372.16" upper_limit="578.82"/>
                    <measurement group_id="O6" value="958.74" lower_limit="792.78" upper_limit="1159.45"/>
                    <measurement group_id="O7" value="1370.55" lower_limit="1115.61" upper_limit="1683.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1168.56" lower_limit="915.50" upper_limit="1491.57"/>
                    <measurement group_id="O4" value="1081.64" lower_limit="750.47" upper_limit="1558.93"/>
                    <measurement group_id="O5" value="626.09" lower_limit="509.37" upper_limit="769.57"/>
                    <measurement group_id="O6" value="816.33" lower_limit="676.78" upper_limit="984.64"/>
                    <measurement group_id="O7" value="1151.62" lower_limit="939.64" upper_limit="1411.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1078.35" lower_limit="839.60" upper_limit="1385.00"/>
                    <measurement group_id="O4" value="967.42" lower_limit="665.58" upper_limit="1406.14"/>
                    <measurement group_id="O5" value="579.56" lower_limit="463.07" upper_limit="725.34"/>
                    <measurement group_id="O6" value="765.63" lower_limit="642.61" upper_limit="912.20"/>
                    <measurement group_id="O7" value="1072.70" lower_limit="854.84" upper_limit="1346.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="866.23" lower_limit="673.55" upper_limit="1114.04"/>
                    <measurement group_id="O4" value="763.51" lower_limit="514.29" upper_limit="1133.49"/>
                    <measurement group_id="O5" value="548.46" lower_limit="439.44" upper_limit="684.53"/>
                    <measurement group_id="O6" value="631.44" lower_limit="511.84" upper_limit="778.99"/>
                    <measurement group_id="O7" value="900.59" lower_limit="716.04" upper_limit="1132.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 271</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="796.48" lower_limit="607.83" upper_limit="1043.70"/>
                    <measurement group_id="O4" value="579.19" lower_limit="329.21" upper_limit="1018.98"/>
                    <measurement group_id="O5" value="546.80" lower_limit="435.46" upper_limit="686.62"/>
                    <measurement group_id="O6" value="565.08" lower_limit="460.42" upper_limit="693.53"/>
                    <measurement group_id="O7" value="690.36" lower_limit="552.52" upper_limit="862.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="746.01" lower_limit="594.45" upper_limit="936.22"/>
                    <measurement group_id="O4" value="814.32" lower_limit="515.32" upper_limit="1286.80"/>
                    <measurement group_id="O5" value="573.22" lower_limit="458.58" upper_limit="716.51"/>
                    <measurement group_id="O6" value="533.55" lower_limit="426.01" upper_limit="668.23"/>
                    <measurement group_id="O7" value="692.93" lower_limit="554.05" upper_limit="866.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rises (GMFRs) of Serum Antibodies Against RSV by RSV A Microneutralization Assay</title>
        <description>GMFRs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay from Baseline line through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.</description>
        <time_frame>Day 29, 61, 91, 181, 271, and 361</time_frame>
        <population>Immunogenicity Population. Here, ‘n’ is number of participants analyzed for this outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rises (GMFRs) of Serum Antibodies Against RSV by RSV A Microneutralization Assay</title>
          <description>GMFRs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay from Baseline line through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.</description>
          <population>Immunogenicity Population. Here, ‘n’ is number of participants analyzed for this outcome measure at given time points.</population>
          <units>Fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" lower_limit="1.96" upper_limit="2.99"/>
                    <measurement group_id="O2" value="3.26" lower_limit="2.29" upper_limit="4.63"/>
                    <measurement group_id="O3" value="2.50" lower_limit="2.11" upper_limit="2.97"/>
                    <measurement group_id="O4" value="2.41" lower_limit="1.82" upper_limit="3.20"/>
                    <measurement group_id="O5" value="0.92" lower_limit="0.86" upper_limit="0.97"/>
                    <measurement group_id="O6" value="2.63" lower_limit="2.17" upper_limit="3.18"/>
                    <measurement group_id="O7" value="2.64" lower_limit="2.12" upper_limit="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" lower_limit="2.21" upper_limit="3.17"/>
                    <measurement group_id="O4" value="2.14" lower_limit="1.60" upper_limit="2.87"/>
                    <measurement group_id="O5" value="1.24" lower_limit="1.08" upper_limit="1.42"/>
                    <measurement group_id="O6" value="2.24" lower_limit="1.81" upper_limit="2.76"/>
                    <measurement group_id="O7" value="2.20" lower_limit="1.79" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" lower_limit="2.05" upper_limit="2.92"/>
                    <measurement group_id="O4" value="1.92" lower_limit="1.43" upper_limit="2.56"/>
                    <measurement group_id="O5" value="1.14" lower_limit="1.04" upper_limit="1.25"/>
                    <measurement group_id="O6" value="2.10" lower_limit="1.70" upper_limit="2.59"/>
                    <measurement group_id="O7" value="2.07" lower_limit="1.65" upper_limit="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="1.72" upper_limit="2.30"/>
                    <measurement group_id="O4" value="1.51" lower_limit="1.20" upper_limit="1.91"/>
                    <measurement group_id="O5" value="1.15" lower_limit="1.02" upper_limit="1.30"/>
                    <measurement group_id="O6" value="1.73" lower_limit="1.44" upper_limit="2.08"/>
                    <measurement group_id="O7" value="1.68" lower_limit="1.37" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 271</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" lower_limit="1.57" upper_limit="2.14"/>
                    <measurement group_id="O4" value="1.08" lower_limit="0.64" upper_limit="1.81"/>
                    <measurement group_id="O5" value="1.11" lower_limit="0.96" upper_limit="1.27"/>
                    <measurement group_id="O6" value="1.56" lower_limit="1.32" upper_limit="1.86"/>
                    <measurement group_id="O7" value="1.42" lower_limit="1.18" upper_limit="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="1.50" upper_limit="1.96"/>
                    <measurement group_id="O4" value="1.47" lower_limit="1.12" upper_limit="1.93"/>
                    <measurement group_id="O5" value="1.15" lower_limit="1.00" upper_limit="1.31"/>
                    <measurement group_id="O6" value="1.50" lower_limit="1.27" upper_limit="1.77"/>
                    <measurement group_id="O7" value="1.34" lower_limit="1.14" upper_limit="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Post-dose Seroresponse to RSV by RSV A Microneutralization Assay</title>
        <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise in titer from baseline. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.</description>
        <time_frame>Day 29</time_frame>
        <population>Immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Post-dose Seroresponse to RSV by RSV A Microneutralization Assay</title>
          <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise in titer from baseline. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.</description>
          <population>Immunogenicity population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" lower_limit="25.57" upper_limit="57.90"/>
                    <measurement group_id="O2" value="42.1" lower_limit="26.31" upper_limit="59.18"/>
                    <measurement group_id="O3" value="42.5" lower_limit="27.04" upper_limit="59.11"/>
                    <measurement group_id="O4" value="30.0" lower_limit="11.89" upper_limit="54.28"/>
                    <measurement group_id="O5" value="0" lower_limit="0.00" upper_limit="8.22"/>
                    <measurement group_id="O6" value="35.0" lower_limit="20.63" upper_limit="51.68"/>
                    <measurement group_id="O7" value="40.5" lower_limit="24.75" upper_limit="57.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations of Serum Antibodies Against RSV by Anti F Immunoglobulin G (IgG) Assay</title>
        <description>Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.</description>
        <time_frame>Baseline (Day 1), Day 29, 61, 91, 181, 271, and 361</time_frame>
        <population>Immunogenicity Population. Here, ‘n’ is number of participants analyzed for this outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations of Serum Antibodies Against RSV by Anti F Immunoglobulin G (IgG) Assay</title>
          <description>Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.</description>
          <population>Immunogenicity Population. Here, ‘n’ is number of participants analyzed for this outcome measure at given time points.</population>
          <units>F Ab Unit/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="44"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.63" lower_limit="74.22" upper_limit="133.73"/>
                    <measurement group_id="O2" value="95.29" lower_limit="62.83" upper_limit="144.54"/>
                    <measurement group_id="O3" value="101.51" lower_limit="75.45" upper_limit="136.58"/>
                    <measurement group_id="O4" value="67.93" lower_limit="30.62" upper_limit="150.71"/>
                    <measurement group_id="O5" value="92.34" lower_limit="76.64" upper_limit="111.25"/>
                    <measurement group_id="O6" value="70.18" lower_limit="55.27" upper_limit="89.11"/>
                    <measurement group_id="O7" value="82.13" lower_limit="64.16" upper_limit="105.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1328.36" lower_limit="958.76" upper_limit="1840.45"/>
                    <measurement group_id="O2" value="1433.98" lower_limit="1053.24" upper_limit="1952.34"/>
                    <measurement group_id="O3" value="1047.68" lower_limit="810.79" upper_limit="1353.79"/>
                    <measurement group_id="O4" value="1003.07" lower_limit="566.77" upper_limit="1775.23"/>
                    <measurement group_id="O5" value="92.94" lower_limit="76.81" upper_limit="112.46"/>
                    <measurement group_id="O6" value="1066.90" lower_limit="836.10" upper_limit="1361.42"/>
                    <measurement group_id="O7" value="1474.47" lower_limit="1110.41" upper_limit="1957.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1050.29" lower_limit="774.32" upper_limit="1424.61"/>
                    <measurement group_id="O4" value="852.27" lower_limit="491.53" upper_limit="1477.76"/>
                    <measurement group_id="O5" value="104.00" lower_limit="80.54" upper_limit="134.30"/>
                    <measurement group_id="O6" value="850.91" lower_limit="661.84" upper_limit="1093.99"/>
                    <measurement group_id="O7" value="1097.04" lower_limit="816.40" upper_limit="1474.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="817.05" lower_limit="603.67" upper_limit="1105.86"/>
                    <measurement group_id="O4" value="662.15" lower_limit="375.50" upper_limit="1167.62"/>
                    <measurement group_id="O5" value="95.29" lower_limit="77.73" upper_limit="116.82"/>
                    <measurement group_id="O6" value="705.96" lower_limit="547.07" upper_limit="910.99"/>
                    <measurement group_id="O7" value="845.04" lower_limit="636.42" upper_limit="1122.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501.47" lower_limit="368.62" upper_limit="682.20"/>
                    <measurement group_id="O4" value="403.58" lower_limit="226.56" upper_limit="718.92"/>
                    <measurement group_id="O5" value="91.54" lower_limit="74.62" upper_limit="112.29"/>
                    <measurement group_id="O6" value="466.81" lower_limit="363.97" upper_limit="598.71"/>
                    <measurement group_id="O7" value="531.43" lower_limit="398.10" upper_limit="709.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 271</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389.94" lower_limit="286.92" upper_limit="529.96"/>
                    <measurement group_id="O4" value="341.99" lower_limit="160.13" upper_limit="730.40"/>
                    <measurement group_id="O5" value="92.70" lower_limit="75.46" upper_limit="113.88"/>
                    <measurement group_id="O6" value="356.11" lower_limit="276.99" upper_limit="457.84"/>
                    <measurement group_id="O7" value="423.30" lower_limit="316.79" upper_limit="565.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343.64" lower_limit="255.99" upper_limit="461.32"/>
                    <measurement group_id="O4" value="284.56" lower_limit="140.69" upper_limit="575.55"/>
                    <measurement group_id="O5" value="94.10" lower_limit="74.03" upper_limit="119.61"/>
                    <measurement group_id="O6" value="305.10" lower_limit="235.90" upper_limit="394.60"/>
                    <measurement group_id="O7" value="354.13" lower_limit="268.29" upper_limit="467.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFRs of Serum Antibodies Against RSV by Anti F IgG Assay</title>
        <description>The Anti F IgG antibodies were derived from the RSV-specific 4-plex MSD assay developed on the Meso Scale discovery platform. Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.</description>
        <time_frame>Day 29, 61, 91, 181, 271, and 361</time_frame>
        <population>Immunogenicity Population. Here, ‘n’ is number of participants analyzed for this outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFRs of Serum Antibodies Against RSV by Anti F IgG Assay</title>
          <description>The Anti F IgG antibodies were derived from the RSV-specific 4-plex MSD assay developed on the Meso Scale discovery platform. Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.</description>
          <population>Immunogenicity Population. Here, ‘n’ is number of participants analyzed for this outcome measure at given time points.</population>
          <units>Fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="43"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.33" lower_limit="9.39" upper_limit="18.93"/>
                    <measurement group_id="O2" value="15.15" lower_limit="10.18" upper_limit="22.55"/>
                    <measurement group_id="O3" value="10.32" lower_limit="7.87" upper_limit="13.54"/>
                    <measurement group_id="O4" value="14.77" lower_limit="7.63" upper_limit="28.59"/>
                    <measurement group_id="O5" value="0.99" lower_limit="0.96" upper_limit="1.02"/>
                    <measurement group_id="O6" value="15.20" lower_limit="11.29" upper_limit="20.47"/>
                    <measurement group_id="O7" value="17.95" lower_limit="14.06" upper_limit="22.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="42"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.54" lower_limit="7.73" upper_limit="14.37"/>
                    <measurement group_id="O4" value="12.55" lower_limit="6.55" upper_limit="24.04"/>
                    <measurement group_id="O5" value="1.09" lower_limit="0.91" upper_limit="1.32"/>
                    <measurement group_id="O6" value="12.13" lower_limit="9.20" upper_limit="15.98"/>
                    <measurement group_id="O7" value="13.35" lower_limit="10.51" upper_limit="16.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.20" lower_limit="6.09" upper_limit="11.05"/>
                    <measurement group_id="O4" value="9.75" lower_limit="5.37" upper_limit="17.70"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.95" upper_limit="1.05"/>
                    <measurement group_id="O6" value="10.06" lower_limit="7.74" upper_limit="13.07"/>
                    <measurement group_id="O7" value="10.28" lower_limit="8.18" upper_limit="12.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="40"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" lower_limit="3.89" upper_limit="6.50"/>
                    <measurement group_id="O4" value="5.94" lower_limit="3.58" upper_limit="9.85"/>
                    <measurement group_id="O5" value="0.97" lower_limit="0.92" upper_limit="1.02"/>
                    <measurement group_id="O6" value="6.65" lower_limit="5.23" upper_limit="8.47"/>
                    <measurement group_id="O7" value="6.23" lower_limit="5.01" upper_limit="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 271</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="39"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.91" lower_limit="3.05" upper_limit="5.02"/>
                    <measurement group_id="O4" value="4.92" lower_limit="3.11" upper_limit="7.77"/>
                    <measurement group_id="O5" value="0.96" lower_limit="0.91" upper_limit="1.01"/>
                    <measurement group_id="O6" value="5.14" lower_limit="4.09" upper_limit="6.44"/>
                    <measurement group_id="O7" value="4.75" lower_limit="3.76" upper_limit="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" lower_limit="2.74" upper_limit="4.33"/>
                    <measurement group_id="O4" value="4.22" lower_limit="2.61" upper_limit="6.80"/>
                    <measurement group_id="O5" value="0.96" lower_limit="0.91" upper_limit="1.02"/>
                    <measurement group_id="O6" value="4.47" lower_limit="3.55" upper_limit="5.65"/>
                    <measurement group_id="O7" value="4.07" lower_limit="3.29" upper_limit="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Post-dose Seroresponse to RSV by Anti-F IgG Assay</title>
        <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise from baseline. Humoral immunity against RSV was assessed by an Anti-F IgG assay derived from the RSV-specific 4-plex MSD assay.</description>
        <time_frame>Day 29</time_frame>
        <population>Immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Post-dose Seroresponse to RSV by Anti-F IgG Assay</title>
          <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise from baseline. Humoral immunity against RSV was assessed by an Anti-F IgG assay derived from the RSV-specific 4-plex MSD assay.</description>
          <population>Immunogenicity population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="82.68" upper_limit="99.37"/>
                    <measurement group_id="O2" value="89.5" lower_limit="75.20" upper_limit="97.06"/>
                    <measurement group_id="O3" value="90.0" lower_limit="76.34" upper_limit="97.21"/>
                    <measurement group_id="O4" value="85.0" lower_limit="62.11" upper_limit="96.79"/>
                    <measurement group_id="O5" value="0" lower_limit="0.00" upper_limit="8.22"/>
                    <measurement group_id="O6" value="97.5" lower_limit="86.84" upper_limit="99.94"/>
                    <measurement group_id="O7" value="97.3" lower_limit="85.84" upper_limit="99.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratios of GMTs and GMFRs of Hemagglutination Inhibition (HAI) Antibodies</title>
        <description>The ratio of post-dose HAI antibody GMTs and GMFRs in the IIV group and the MEDI7510 plus IIV group was provided by strain and by cohort for Cohorts 2 and 3 to check the effect of MEDI7510 on IIV when administered together. Humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed on Day 29 by each strain (H1N1, H3N2, B/Yamagata).</description>
        <time_frame>Day 29</time_frame>
        <population>Immunogenicity Population.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratios of GMTs and GMFRs of Hemagglutination Inhibition (HAI) Antibodies</title>
          <description>The ratio of post-dose HAI antibody GMTs and GMFRs in the IIV group and the MEDI7510 plus IIV group was provided by strain and by cohort for Cohorts 2 and 3 to check the effect of MEDI7510 on IIV when administered together. Humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed on Day 29 by each strain (H1N1, H3N2, B/Yamagata).</description>
          <population>Immunogenicity Population.</population>
          <units>Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT: H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O2" value="1.19" lower_limit="0.71" upper_limit="1.99"/>
                    <measurement group_id="O3" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O4" value="1.01" lower_limit="0.63" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT: H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O2" value="1.53" lower_limit="1.03" upper_limit="2.28"/>
                    <measurement group_id="O3" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O4" value="0.78" lower_limit="0.53" upper_limit="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT: B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O2" value="1.38" lower_limit="0.81" upper_limit="2.36"/>
                    <measurement group_id="O3" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O4" value="1.49" lower_limit="0.91" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR: H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O2" value="1.13" lower_limit="0.68" upper_limit="1.87"/>
                    <measurement group_id="O3" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O4" value="0.97" lower_limit="0.54" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR: H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O2" value="1.53" lower_limit="0.86" upper_limit="2.72"/>
                    <measurement group_id="O3" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O4" value="1.28" lower_limit="0.69" upper_limit="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR: B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O2" value="1.09" lower_limit="0.76" upper_limit="1.55"/>
                    <measurement group_id="O3" value="NA">Data is not available for this time point because the humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed.</measurement>
                    <measurement group_id="O4" value="1.00" lower_limit="0.71" upper_limit="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Counts of Cellular Immune Response Against RSV by Respiratory Syncytial Virus Fusion Protein (RSV F) Interferon Gamma (IFNγ) Enzyme-linked Immunosorbent Spot (ELISPOT) Assay</title>
        <description>The Geometric Mean Counts assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.</description>
        <time_frame>Baseline (Day 1) and Day 8</time_frame>
        <population>Immunogenicity Population. Here, ‘n’ is number of participants analyzed for this outcome measure at given time points.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Counts of Cellular Immune Response Against RSV by Respiratory Syncytial Virus Fusion Protein (RSV F) Interferon Gamma (IFNγ) Enzyme-linked Immunosorbent Spot (ELISPOT) Assay</title>
          <description>The Geometric Mean Counts assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.</description>
          <population>Immunogenicity Population. Here, ‘n’ is number of participants analyzed for this outcome measure at given time points.</population>
          <units>Spot forming counts per 10^6 PBMCs</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.06" lower_limit="53.40" upper_limit="81.72"/>
                    <measurement group_id="O2" value="47.21" lower_limit="39.96" upper_limit="55.77"/>
                    <measurement group_id="O3" value="50.89" lower_limit="42.19" upper_limit="61.38"/>
                    <measurement group_id="O4" value="42.24" lower_limit="33.84" upper_limit="52.73"/>
                    <measurement group_id="O5" value="58.53" lower_limit="47.10" upper_limit="72.74"/>
                    <measurement group_id="O6" value="45.71" lower_limit="38.90" upper_limit="53.71"/>
                    <measurement group_id="O7" value="62.63" lower_limit="49.89" upper_limit="78.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="40"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436.72" lower_limit="333.87" upper_limit="571.25"/>
                    <measurement group_id="O2" value="341.02" lower_limit="222.54" upper_limit="522.58"/>
                    <measurement group_id="O3" value="430.33" lower_limit="308.22" upper_limit="600.83"/>
                    <measurement group_id="O4" value="379.28" lower_limit="225.90" upper_limit="636.80"/>
                    <measurement group_id="O5" value="54.30" lower_limit="43.86" upper_limit="67.24"/>
                    <measurement group_id="O6" value="376.43" lower_limit="273.42" upper_limit="518.25"/>
                    <measurement group_id="O7" value="618.15" lower_limit="463.46" upper_limit="824.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFRs of Cellular Immune Response Against RSV by RSV F IFNγ ELISPOT Assay</title>
        <description>The GMFRs assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples</description>
        <time_frame>Day 8</time_frame>
        <population>Immunogenicity Population.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFRs of Cellular Immune Response Against RSV by RSV F IFNγ ELISPOT Assay</title>
          <description>The GMFRs assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples</description>
          <population>Immunogenicity Population.</population>
          <units>Fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" lower_limit="4.88" upper_limit="8.52"/>
                    <measurement group_id="O2" value="6.77" lower_limit="4.13" upper_limit="11.09"/>
                    <measurement group_id="O3" value="8.67" lower_limit="6.38" upper_limit="11.78"/>
                    <measurement group_id="O4" value="8.87" lower_limit="4.99" upper_limit="15.77"/>
                    <measurement group_id="O5" value="0.89" lower_limit="0.76" upper_limit="1.04"/>
                    <measurement group_id="O6" value="8.23" lower_limit="5.92" upper_limit="11.46"/>
                    <measurement group_id="O7" value="10.48" lower_limit="7.82" upper_limit="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Post-dose Cell-mediated Immune Response to RSV F by RSV F Peptide Pool IFNγ ELISPOT</title>
        <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise from baseline. The Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.</description>
        <time_frame>Day 8</time_frame>
        <population>Immunogenicity Population.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
            <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Inactivated Influenza Vaccine (IIV)</title>
            <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + IIV, Cohort 3</title>
            <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Post-dose Cell-mediated Immune Response to RSV F by RSV F Peptide Pool IFNγ ELISPOT</title>
          <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise from baseline. The Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.</description>
          <population>Immunogenicity Population.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" lower_limit="58.83" upper_limit="89.25"/>
                    <measurement group_id="O2" value="80.8" lower_limit="60.65" upper_limit="93.45"/>
                    <measurement group_id="O3" value="90.0" lower_limit="73.47" upper_limit="97.89"/>
                    <measurement group_id="O4" value="78.9" lower_limit="54.43" upper_limit="93.95"/>
                    <measurement group_id="O5" value="0.00" lower_limit="0.00" upper_limit="10.89"/>
                    <measurement group_id="O6" value="82.5" lower_limit="67.22" upper_limit="92.66"/>
                    <measurement group_id="O7" value="97.1" lower_limit="85.08" upper_limit="99.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAEs were collected from time of signature of informed consent throughout the treatment period and including the follow-up period through the Day 29 visit and day of last subject contact (Day 361 visit), respectively</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1</title>
          <description>Participants received single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Inactivated Influenza Vaccine (IIV)</title>
          <description>Participants received single dose of IIV by intramuscular injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + Placebo, Cohort 2</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>MEDI7510 (120 mcg sF + 2.5 mcg GLA) + IIV, Cohort 2</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>MEDI7510 (120 mcg sF + 5 mcg GLA) + Placebo, Cohort 3</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus placebo administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>MEDI7510 (120 mcg sF + 5 mcg GLA)+ IIV, Cohort 3</title>
          <description>Participants received single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV administered by IM injection in contralateral arms on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4</title>
          <description>Participants received single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Wound haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Judith Falloon, MD, FACP, FIDSA, Senior Director, Clinical Development</name_or_title>
      <organization>MedImmune LLC</organization>
      <phone>+1-301-398-4010</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

